Quince Therapeutics, Inc. (QNCX) Institutional Ownership

Ownership Summary

The institutional landscape for Quince Therapeutics, Inc. (NASDAQ:QNCX) includes 45 filers as of the latest reporting cycle ending September 2025.

• These investors collectively held 22.9% of the company's total shares outstanding in September 2025, up from 16.5% in June 2025.
• In percentage terms, this reflects as a holdings change of 59.94% quarter on quarter, and an increase of 36.36% year over year.
• During the quarter, 21 institutions bought more Quince Therapeutics shares, 9 sold shares, and 15 of the 45 total investors held their position steady.
• The total number of shares held by institutions in Quince Therapeutics increased to 12.29Mn as of September 2025, a net change of up by 4.60Mn shares quarter on quarter, and up 7.09Mn shares year over year.
• As of September 30, 2025, Nantahala Capital Management, LLC held Quince Therapeutics's largest shareholding position with over 3.07Mn shares, representing 5.72% of total outstanding shares.
• Among the most significant buyers of Quince Therapeutics during September 2025 were MILLENNIUM MANAGEMENT LLC (1.28Mn), ADAR1 Capital Management, LLC (632.08K), Almitas Capital LLC (606.67K), Nantahala Capital Management, LLC (545.43K), IEQ CAPITAL, LLC (541.99K).
• Leading sellers of Quince Therapeutics stock in September 2025 included BRIDGEWAY CAPITAL MANAGEMENT, LLC (33.49K), Shay Capital LLC (13.04K), NORTHERN TRUST CORP (12.79K), TWO SIGMA INVESTMENTS, LP (2.31K), UBS Group AG (1.37K).
• The top 10 institutional holders of Quince Therapeutics for the quarter ending September 2025 included Nantahala Capital Management, LLC (3.07Mn), VANGUARD GROUP INC (1.76Mn), MILLENNIUM MANAGEMENT LLC (1.39Mn), Almitas Capital LLC (989.56K), IEQ CAPITAL, LLC (981.26K), ADAR1 Capital Management, LLC (775.03K), RENAISSANCE TECHNOLOGIES LLC (468.60K), GEODE CAPITAL MANAGEMENT, LLC (437.29K), BlackRock, Inc. (345.46K), HighTower Advisors, LLC (308.50K).